US2021140972A1PendingUtilityA1

Mechanism of action

77
Assignee: UCB Biopharma SRLPriority: Jun 18, 2015Filed: Oct 16, 2020Published: May 13, 2021
Est. expiryJun 18, 2035(~8.9 yrs left)· nominal 20-yr term from priority
G01N 2500/04G01N 2333/7151G01N 2333/525G01N 33/6863C07K 2317/92C07K 2317/565C07K 2317/34C07K 2317/32C07D 471/04C07D 401/14C07D 401/04A61P 35/00G01N 33/6845C07K 2317/24C07K 2317/55C07K 14/70575C07K 14/525C07K 16/241A61K 47/6425C07D 471/00G01N 2500/02A61P 37/00C07D 235/04C07D 239/26C07D 213/72G01N 33/6854
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A compound of formula (5), or a pharmaceutically acceptable salt or solvate thereof: 
       
         
           
           
               
               
           
         
       
     
     
         22 . A complex comprising a trimeric protein that is a tumor necrosis factor (TNF) superfamily member and the compound of  claim 21 . 
     
     
         23 . (canceled) 
     
     
         24 . A method of treating and/or preventing a disorder selected from an autoimmune, an inflammatory, a neurological, a neurodegenerative, a pain, a nociceptive, and a cardiovascular disorders in a subject in need thereof, comprising administering the compound of  claim 21  to the subject. 
     
     
         25 . The method of  claim 24 , wherein rheumatoid arthritis, Crohn's disease, psoriasis, systemic lupus erythematosus, Alzheimer's disease, Parkinson's disease or epilepsy is treated and/or prevented. 
     
     
         26 . A pharmaceutical composition comprising the compound of  claim 21  and a pharmaceutically acceptable carrier. 
     
     
         27 . A method of treating and/or preventing a disorder selected from an autoimmune, an inflammatory, a neurological, a neurodegenerative, a pain, a nociceptive, and a cardiovascular disorder in a subject in need thereof, comprising administering the complex of  claim 22  to the subject. 
     
     
         28 . A pharmaceutical composition comprising the complex of  claim 22  and a pharmaceutically acceptable carrier. 
     
     
         29 . The method of  claim 27 , wherein rheumatoid arthritis, Crohn's disease, psoriasis, systemic lupus erythematosus, Alzheimer's disease, Parkinson's disease or epilepsy is treated and/or prevented.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.